Reduction by (-)-cicletanine of the vascular reactivity to angiotensin II in rats

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 4, 1996, Pages 564-570

  Alvarez Guerra, Miriam ^a   Alda, Octavio ^b   Morin, Elisabeth ^c   Allard, Michel ^c   Garay, Ricardo P ^a  

^a INSERM   (France)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c IPSEN   (France)

Author keywords

Angiotensin II; Cicletanine; Vascular smooth muscle; Vasopressin

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN; ARGIPRESSIN[1 (3,3 CYCLOPENTAMETHYLENE 3 MERCAPTOPROPIONIC ACID) 2 (O METHYLTYROSINE)]; CICLETANINE; IDAZOXAN; LOSARTAN; METHYSERGIDE; PRAZOSIN; SEROTONIN; TALIPEXOLE; TUBOCURARINE CHLORIDE; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BLOOD VESSEL REACTIVITY; CAROTID ARTERY; CONTROLLED STUDY; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RACEMIC MIXTURE; RAT; SPINAL CORD STIMULATION;

EID: 0029759702     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199610000-00014     Document Type: Article

References (17)

1. Chabrier PE, Guinot P, Tarrade T, et al. Cicletanine. Cardiovasc Drug Rev 1988;6:166-79.
2. Ebeigbe AB, Cabanié M, Godfraind T. Effects of cicletanine on histamine-induced contractions of isolated rabbit mesenteric arteries. Fund Clin Pharmacol 1989;3:223-35.
3. m cyclic GMP phosphodiesterases and potentiation of guanylate cyclase activators by cicletanine. J Cardiovasc Pharmacol 1990;16:501-5.
4. ++-regulated protein kinases and relationship to vasorelaxation by cicletanine. J Pharmacol Expl Ther 1991;257:382-91.
5. Buchholz RA, Brousseau A, Silver PJ. Natriuretic and diuretic effects of cicletanine in conscious, hydrated, normotensive rats. Drug Dev Res 1992;25:125-37.
6. Garay RP, Rosati C, Fanous K, et al. Evidence for (+)-cicletanine sulfate as an active natriuretic metabolite of cicletanine in the rat. Eur J Pharmacol 1995;274:175-80.
7. Moulin B, Fillastre JP, Godin M, Coquerel A, Decoopman E. Renal hemodynamics and sodium excretion after acute and chronic administration of cicletanine in normotensive and hypertensive subjects. J Cardiovasc Pharmacol 1995;25:292-9.
8. Cavero I, Lefèvre-Borg F, Roach AG, Scatton B. Functional and biochemical evidence for the lack of cardiac presynaptic alpha-2 adrenoceptor agonist properties of cirazoline (LD 3098), a vasoconstrictor imidazoline. J Pharmacol Exp Ther 1982;223:241-50.
9. Gomeni R, Gomeni C. A conversational graphic program for the analysis of the sigmoid curve. Comput Biomed Res 1980;13:489-99.
10. Arunlakshama O, Schild MO. Some quantitative uses of drug antagonists. Br J Pharmacol 1956;14:48-48.
11. Fredj G. Clinical pharmacokinetics of cicletanine hydrochloride. Drugs Exp Clin Res 1988;14:181-8.
12. Johnson JA, Kennedy CD. Robinson DT. Stereoselective disposition and biotransformation of cicletanine racemate hydrochloride. Proceedings of the 5th North American Meeting of the International Society for the Study of Xenobiotics, Tucson, Arizona, October 17-20, 1993.
13. Vistelle R, Lamiable D, Morin E, Trenque T, Kaltenbach M. Urinary excretion of cicletanine in the rat. Stereochemical aspects. Drug Metab Dispos 1995;23:988-92.
14. Bouthier JA, Safar ME, Deschamps E, Tarrade T. Hemodynamic effects of an antihypertensive diuretic substance on the forearm circulation of patients with essential hypertension. Drugs Exp Clin Res 1988;14:221-4.
15. Guinot P, Jewitt-Harris J, Tarrade T. Determination of the optimal dose of the antihypertensive drug cicletanine hydrochloride in man. Arzneimittelforschung Drug Res 1989;39:86-9.
16. Silver PJ, Cumiskey WR. Uptake of cicletanine by vascular smooth muscle. Drug Dev Res 1991;23:275-80.
17. Trapani AJ, Smits GJ, McGraw DE, McMahon EG, Blaine EH. Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor. J Pharmacol Exp Ther 1991;258:269-74.